Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampreloxetine in symptomatic nOH (OAK)
NCT04095793Phase 3Terminated
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Sep 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH), sponsored by Theravance Biopharma, Inc.. Started Sep 2019; status: terminated.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT04095793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04095793.